-
Can’t Get You Out of My Head: The Huntington’s Disease Symptom That’s More Than Just Repetition
5 min read
Latest News
-
AMT-130 at Four Years: Hopeful Signs, Complex Controls
12 min read
uniQure reports that after 4 years, people given high-dose AMT-130 continue to show signs of slower HD progression, providing hope for their recent regulatory submission. But the new analyses are nuanced. We unpack the hopeful, but complex results.
-
Getting to the Root of Huntington's Disease: A Plant-Based Approach
5 min read
Researchers used plants to study how to stop the Huntington’s disease protein from forming toxic clumps
-
Could halting CAG expansions be a new treatment for HD?
7 min read
The gene MSH3 is getting a lot of attention in HD research lately. New findings suggest MSH3 lowering could halt CAG repeat expansions, offering a new therapeutic avenue.
-
Tipping the balance; new insights into HD genetic modifiers
5 min read
A new study from researchers at Thomas Jefferson University delves into the details of how genetic modifiers of Huntington’s disease work.
-
Drug to treat movement symptoms of HD approved by FDA
6 min read
The FDA has approved valbenazine, also known as INGREZZA, as a treatment for the movement symptoms of Huntington’s disease
-
Youthful competitors: young brain cells oust the old
5 min read
Replacing cells with HD in the brain could be an effective treatment strategy. Recent work shows that glia injected into mouse brains take over and oust the older cells, but for a surprising reason – because of age, not HD!
-
Updates from PTC Therapeutics and uniQure on their huntingtin-lowering trials
11 min read
Both PTC Therapeutics and uniQure have shared updates from their respective clinical trials, testing different huntingtin-lowering approaches. We explore the data presented from both of these studies and what this means for HD family members.
-
Huntington’s disease therapeutics conference 2023 – Day 3
18 min read
Check out research updates from Day 3 of the 2022 HD Therapeutics Conference #HDTC2023
-
Huntington’s disease therapeutics conference 2023 – Day 2
15 min read
Check out research updates from Day 2 of the 2022 HD Therapeutics Conference #HDTC2023
-
Huntington’s disease therapeutics conference 2023 – Day 1
23 min read
Check out research updates from Day 1 of the 2022 HD Therapeutics Conference #HDTC2023
-
PROOF-HD study of pridopidine ends with negative result
5 min read
The phase 3 trial missed its primary endpoint of slowing loss of function in Huntington’s disease
HDBuzz Trial Tracker
Show 8 more Show less
Updates from the ongoing Phase 3 INVEST-HD trial of votoplam
Updates from the Phase 1b/2a REGEN4HD trial of neural stem cell therapy hNSC-01
Updates from the ongoing Phase 2/3 FALCON-HD trial of SKY-0515
